Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza, Human
Interventions: Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 22
States / cities: Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more

Conditions: COVID-19 Respiratory Infection, Influenza
Interventions: RD-X19, RD-X19 Sham; Device
Lead sponsor: David Moss; Federal
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more

Conditions: Influenza
Interventions: A/Arkansas/08/2020 (pH1N1), Sham/Diluent (1X SPG+Arg+Gel); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: St Louis, Missouri • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4); Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 1,500,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza Virus
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
Interventions: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more

Conditions: Influenza
Interventions: Split, Inactivated, Trivalent Influenza vaccine (Fluzone®); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV); Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 65 Years and older
Enrollment: 7,109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Phoenix, Arizona • DeLand, Florida • Jacksonville, Florida + 15 more

Conditions: Influenza
Interventions: AVX502, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Multiple Sclerosis
Interventions: Plegridy, Prednisone, Tylenol Pill; Drug
Lead sponsor: Holy Name Medical Center, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Teaneck, New Jersey

Conditions: Influenza
Interventions: Free Air Portable Air Powered Respirator, N95 Respirator; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 49 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Influenza
Interventions: CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone); Biological
Lead sponsor: Seqirus; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 1,474 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more

Conditions: Influenza Infection, Infections, Respiratory Virus Infections, Respiratory Tract Infections, RNA Viruses, Orthomyxoviridae Infections, Viral Diseases
Interventions: A/Mallard/Ohio-99/MM4/1989 H10N7; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Post Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 64 Years
Enrollment: 4,138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 43
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more

Conditions: Influenza
Interventions: Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine; Biological
Lead sponsor: Colby Pharmaceutical Company; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza
Interventions: Personal Protective Equipment (PPE) - Under High Air Hygiene, No Intervention - Under High Air Hygiene, Personal Protective Equipment (PPE) - Under Low Air Hygiene, No Intervention - Under Low Air Hygiene; Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 59 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • College Park, Maryland

Conditions: Influenza
Interventions: FluBlok®, Placebo; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 4,648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 24
States / cities: Beverly Hills, California • Sacramento, California • San Francisco, California + 20 more

Conditions: Rheumatoid Arthritis
Interventions: Influenza vaccine; Biological
Lead sponsor: Bassett Healthcare; Other
Eligibility: 40 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Interventions: Fludarabine, Melphalan, Total Body Irradiation; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Stress
Interventions: R-CBSM, Influenza vaccine; Behavioral · Biological
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Influenza
Interventions: VAX102; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

H5 Vaccine Alone or With Adjuvant in Healthy Adults

pH1N1 Blinded Challenge Study

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults

A Study of Modified mRNA Vaccines in Healthy Adults

A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination

Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects

A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Evaluation of Free Air Portable Air Powered Respirator

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza

Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

DMID 21-0041; Influenza CVD 59000

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Duration of Immune Response to Influenza Vaccination in Patients With RA

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)

Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults